The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Clinical Trial

Official title:

The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02126592
• Other study ID #: 12XJ10015
• Status: Recruiting
• Phase: N/A
• First received: January 21, 2014
• Last updated: April 28, 2014
• Start date: March 2013
• Est. completion date: May 2014

Study information

• Verified date: January 2014
• Source: RenJi Hospital
• Contact: Jing Ma, Dr.
• Phone: +86-21-68383083
• Email: cherry1996[@]live.cn
• Is FDA regulated: No
• Health authority: China:Research Committee of Shanghai Renji Hospital
• Study type: Observational

Clinical Trial Summary

Polycystic ovary syndrome (PCOS) is an endocrine disease in reproductive women. It is characterized by anovulation and hyperandrogenism. Most patients with PCOS have metabolic abnormalities such as dyslipidemia, insulin resistance and glucose abnormalities. Almost 60-80﹪PCOS patients are obesity which exacerbates IR and hyperandrogenism. Obese PCOS patients tend to be overeating suggests that impaired appetite regulation might be contribute to the pathophysiology of PCOS. Our study is trying to observe difference of incretin between PCOS and normal control to figure out whether change of incretin is involved in the pathophysiology of PCOS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 13 Years to 45 Years

Eligibility

Inclusion Criteria:

• women at reproductive age

• women with PCOS and women without PCOS

Exclusion Criteria:

• young women who had their menarche less than 3 years

• women older than 45 years old, Amenorrhea of menopause, hyperglycemia, hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia, dystrophy, gonitis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Polycystic Ovary Syndrome
• Syndrome

Locations

Country	Name	City	State
China	Renji Hospital	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
RenJi Hospital	Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in incretin hormones secretion in PCOS patients.		up to 14 months	No